HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--April 21, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News) is pleased to report that the Company’s new updated review of safety data for its ongoing multi-center Phase 2 trial of NX-1207 has revealed no serious drug side effects. NX-1207 is Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH).
NX-1207 has completed two earlier Phase 1 and 2 trials where the drug produced on average over 23% prostate shrinkage in 1 month with minimal side effects. Overall there have been no sexual side effects, and a better side effect profile compared to existing drugs. The symptomatic improvement in earlier trials reached 10 points on the BPH Symptom Score, which is far superior to available drugs, and compares to invasive and surgical treatments.
Previously (January 23, 2006) Nymox reported that the Independent Data Monitoring Committee for the trial of NX-1207 had given a positive recommendation based on evaluation of the efficacy and safety data at that point in time. The Independent Data Monitoring Committee is an arm’s length independent body which has examined unblinded trial results and reached a favorable conclusion, and has recommended continuation of the trial.
BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Commission and other regulatory authorities.
Contact:
Nymox Pharmaceutical Corporation Roy Wolvin, 1-800-93NYMOX website: www.nymox.com
Source: Nymox Pharmaceutical Corporation
